Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $1.52 per share for the quarter. Collegium Pharmaceutical has set its FY 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. During the same quarter in the prior year, the company earned $1.13 EPS. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Trading Down 1.6 %

Shares of NASDAQ COLL opened at $34.67 on Thursday. Collegium Pharmaceutical has a 1-year low of $21.40 and a 1-year high of $42.29. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71. The company has a 50-day moving average of $37.62 and a two-hundred day moving average of $35.29. The company has a market cap of $1.13 billion, a PE ratio of 14.45 and a beta of 0.94.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on COLL shares. Truist Financial increased their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright upped their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.